Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clariane SECHIX:CLARIP 62 EV-to-EBIT is 27.65 as of Jul. 19, 2026, which is 0% below its 10-year median of 27.69. GuruFocus rates CHIX:CLARIP with a GF Score™ of 62/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Clariane SE ranks worse than 73.29% on this metric.
The historical rank and industry rank for Clariane SE's EV-to-EBIT or its related term are showing as below:
CHIX:CLARIp'
s EV-to-EBIT Range Over the Past 10 Years
Min: 16.75 Med: 27.69 Max: 42.79
Current: 27.65
During the past 13 years, the highest EV-to-EBIT of Clariane SE was 42.79. The lowest was 16.75. And the median was 27.69.
CHIX:CLARIp's EV-to-EBIT is ranked worse than 73.29% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 15.86
vs CHIX:CLARIp: 27.65
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Clariane SE's Enterprise Value for the quarter that ended in Dec. 2025 was €8,664 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clariane SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €315 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE EV-to-EBIT Related Terms
Clariane SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Clariane SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CLARIP vs HCA, THC, DVA: EV-to-EBIT Comparison
For the Medical Care Facilities subindustry, Clariane SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Clariane SE's EV-to-EBIT falls into.
Clariane SE's current Enterprise Value is €8,707 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clariane SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €315 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE (CHIX:CLARIP) has a EV-to-EBIT of 27.65 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clariane SE and its competitors. This is near median its historical median of 27.69. Over the past decade, Clariane SE's EV-to-EBIT has ranged from 16.75 to 42.79. According to the industry distribution chart, Clariane SE ranks #343 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 73.3%.
Is Clariane SE's EV-to-EBIT too high?
Clariane SE's current EV-to-EBIT of 27.65 is near median its 10-year median of 27.69. Over the past 10 years, this metric has ranged from a low of 16.75 to a high of 42.79. The Healthcare Providers & Services industry median EV-to-EBIT is 15.86. Clariane SE's value of 27.65 is 74.3% above this industry median. Based on the distribution chart, Clariane SE ranks #343 out of 468 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Clariane SE has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #343 out of 468 companies for EV-to-EBIT. This places Clariane SE in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Clariane SE's value of 27.65 is 74.3% above this benchmark. Historically, Clariane SE's own EV-to-EBIT has ranged from 16.75 to 42.79 over the past decade. While the company's 10-year median is 27.69 vs. the industry median of 15.86, Clariane SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.86, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current EV-to-EBIT of 27.65 is 74.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current EV-to-EBIT is 27.65, which is near median its own 10-year median of 27.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current EV-to-EBIT is 27.65, which is near median its 10-year median of 27.69 and 74.3% above the Healthcare Providers & Services industry median of 15.86. Clariane SE's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current EV-to-EBIT is 27.65 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
EV-to-EBIT: 27.65 (near median its 10-year median of 27.69)
GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
Industry Position: 74.3% above the Healthcare Providers & Services median (#343 of 468)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
62GF Score
Get the complete analysis for CHIX:CLARIP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 
